Tobin Schilke, CFO at Revance Therapeutics, Inc. (RVNC), sold 6,402 shares at $33.50 ($214K) on 2023-03-01, disclosed to the SEC on 2023-03-02.
Open-market sale of $214k RVNC by CFO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.50 | 3,201 | $107K | 50.0% |
| 2 | $33.50 | 3,201 | $107K | 50.0% |
| Total | $33.50 avg | 6,402 | $214K | 100% |
| Filing → |
| RVNC | SELL | 2023-07-05 | $43K | — | Filing → |
| RVNC | SELL | 2023-06-05 | $181K | — | Filing → |
| RVNC | SELL | 2023-05-16 | $1.5M | — | Filing → |